Subscribe to MTSL

 

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year, sent either electronically and/or via print mail. In addition to our redesigned and enhanced website — BioInvest.com — MTSL now provides more timely updates, whitepapers and breaking news than ever before. We offer unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility. Our philosophy of buying carefully selected biotech stocks at attractive prices and holding them for the long-term hasn’t changed. What has changed is our ability to make  MTSL a more valuable tool for today’s discerning investor.

To renew your subscription, please re-subscribe at your preferred level below.

INDIVIDUAL SUBSCRIPTION

For the Retail or Individual Investor

 

   1 Year (24 issues) digital only: $399
   1 Year (24 issues) digital + print: $459
   2 Year (48 issues) digital only: $678 (15% savings off annual rate)
   2 Year (48 issues) digital + print: $798 (15% savings off annual rate)
   3 Year (72 issues) digital only: $898 (25% savings off annual rate)
   3 Year (72 issues) digital + print: $1,078 (25% savings off annual rate)

GROUP SUBSCRIPTION

For the Corporate or Institutional Investor**

 

   1 Year (24 issues) digital only: $1,899
   1 Year (24 issues) digital + print: $1,959
   2 Year (48 issues) digital only: $3,228 (15% savings off annual rate)
   2 Year (48 issues) digital + print: $3,348 (15% savings off annual rate)
   3 Year (72 issues) digital only: $4,272 (25% savings off annual rate)
   3 Year (72 issues) digital + print: $4,452 (25% savings off annual rate)

*All rates are for email delivery; add $60 per year for print copy.
**Limited to 50 users per group subscription.

 

*****************************************************
You may cancel at any time for a prorated refund.  The contents are based on information from sources believed to be reliable, but accuracy and completeness cannot be guaranteed.  Nothing herein should be construed as an offer to buy or sell any security.  The publisher and its associates, directors or employees may have positions in, and may from time to time make purchases or sales of, securities mentioned herein. We cannot guarantee and you should not assume that future recommendations will equal the performance of past recommendations or be profitable